Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16224
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Williams, Kathryn H | - |
dc.contributor.author | Sullivan, David R | - |
dc.contributor.author | Nicholson, Geoffrey C | - |
dc.contributor.author | George, Jacob | - |
dc.contributor.author | Jenkins, Alicia J | - |
dc.contributor.author | Januszewski, Andrzej S | - |
dc.contributor.author | Gebski, Val J | - |
dc.contributor.author | Manning, Patrick | - |
dc.contributor.author | Tan, Yong Mong | - |
dc.contributor.author | Donoghoe, Mark W | - |
dc.contributor.author | Ehnholm, Christian | - |
dc.contributor.author | Young, Simon | - |
dc.contributor.author | O'Brien, Richard C | - |
dc.contributor.author | Buizen, Luke | - |
dc.contributor.author | Twigg, Stephen M | - |
dc.contributor.author | Keech, Anthony C | - |
dc.date | 2016-12-21 | - |
dc.date.accessioned | 2016-09-12T05:27:37Z | - |
dc.date.available | 2016-09-12T05:27:37Z | - |
dc.date.issued | 2016-05 | - |
dc.identifier.citation | Metabolism 2016; 65(5): 783-793 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16224 | - |
dc.description.abstract | AIMS: Reported associations between liver enzymes and mortality may not hold true in type 2 diabetes, owing to a high prevalence of non-alcoholic fatty liver disease, which has been linked to cardiovascular disease and mortality in its own right. Our study aimed to determine whether alanine aminotransferase (ALT) or γ-glutamyl transferase (GGT) levels predict mortality in type 2 diabetes, and to examine possible mechanisms. METHODS: Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study were analyzed to examine the relationship between liver enzymes and all-cause and cause-specific mortality over 5years. RESULTS: Over 5years, 679 (6.9%) individuals died. After adjustment, for every standard deviation increase in ALT (13.2U/L), the HR for death on study was 0.85 (95% CI 0.78-0.93), p<0.001. Conversely, GGT >70U/L, compared with GGT ≤70U/L, had HR 1.82 (1.48-2.24), p<0.001. For cause-specific mortality, lower ALT was associated with a higher risk of cardiovascular death only, whereas GGT >70U/L was associated with higher risks of death due to cardiovascular disease, cancer and non-cancer/non-cardiovascular causes. The relationship for ALT persisted after adjustment for indirect measures of frailty but was attenuated by elevated hsCRP. CONCLUSIONS: As in the general population, ALT has a negative, and GGT a positive, correlation with mortality in type 2 diabetes when ALT is less than two times the upper limit of normal. The relationship for ALT appears specific for death due to cardiovascular disease. Links of low ALT with frailty, as a potential mechanism for relationships seen, were neither supported nor conclusively refuted by our analysis and other factors are also likely to be important in those with type 2 diabetes. | en_US |
dc.subject | Mortality | en_US |
dc.subject | Alanine aminotransferase | en_US |
dc.subject | γ-Glutamyl transferase | en_US |
dc.subject | Non-alcoholic fatty liver disease | en_US |
dc.subject | Diabetes mellitus | en_US |
dc.title | Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Metabolism | en_US |
dc.identifier.affiliation | Austin Health, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | Sydney Medical School, University of Sydney, Sydney, NSW, Australia | en_US |
dc.identifier.affiliation | Royal Prince Alfred Hospital, Sydney, NSW, Australia | en_US |
dc.identifier.affiliation | National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia | en_US |
dc.identifier.affiliation | Rural Clinical School, University of Queensland, Brisbane, Queensland, Australia | en_US |
dc.identifier.affiliation | Storr Liver Unit, Westmead Millennium Institute, Westmead Hospital, Sydney, NSW, Australia | en_US |
dc.identifier.affiliation | Department of Medical and Surgical Sciences, Dunedin School of Medicine, Dunedin, New Zealand | en_US |
dc.identifier.affiliation | Townsville Diabetes and Endocrine Unit, Townsville Hospital, Townsville, Queensland, Australia | en_US |
dc.identifier.affiliation | Biomedicum Helsinki, Helsinki, Finland | en_US |
dc.identifier.affiliation | Diabetes Clinic, Northshore Hospital, Auckland, New Zealand | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/27085785 | en_US |
dc.identifier.doi | 10.1016/j.metabol.2015.12.008 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | O'Brien, Richard C | |
item.fulltext | No Fulltext | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | University of Melbourne Clinical School | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.